News | June 21, 2025
Biocon concludes a Rs 4,500 crore equity fundraise through QIP
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
25 women students to receive internship, training, and mentorship in Life Sciences segment
The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis
Subscribe To Our Newsletter & Stay Updated
